Shareholder Update From Biel discussions with-two-major

New Post Public Reply Private Reply Replies (0) Message Board
iwantutowantBIEL
544
Shareholder Update From Biel

discussions with-two-major organizations to rollout the RecoveryRx product


My Guess, B Braun and ?? Cardinal Health?? They are big in Wound Care.

LETTER TO STOCKHOLDERS- July 2, 2019

FDA Market Clearances Update

Post-Operative Pain

On Friday, June 28th, we received market clearance from the US FDA for RecoveryRx® (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K190251). A press release announcing the same was issued on Monday, July 1 (https://www.globenewswire.com/news-release/2019/07/01/1876675/0/en/BioElectronics-Announces-FDA-Market-Clearance-for-Its-Non-Opioid-Postoperative-Pain-Therapy.html).

The Company is in discussions with two major organizations to rollout the RecoveryRx product in the US. Additionally, we are working to list the product with three major drug wholesalers (McKesson Corporation, Cardinal Health and Smith Drug).

Musculoskeletal Pain 510(k)

BioElectronics is currently preparing documentation to file its 510(k) application to seek expanded indications of musculoskeletal pain, using the cervical osteoarthritis (neck pain) study. We are waiting for the full data set from the study investigator and expect to file the 510(k) application within a few weeks.

ActiPatch® is already FDA-cleared for adjunctive treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (2 million annually). The expanded market clearance would allow ActiPatch to be marketed for millions of Americans suffering with a broad range of musculoskeletal conditions: back pain (42 million), neck pain (19 million), hip pain (9 million), shoulder pain (11 million), carpal tunnel pain (12 million) and many other musculoskeletal complaints.

The neck osteoarthritis study investigates the effectiveness of ActiPatch in reducing pain both in men and women and satisfies the FDA requirement for a third ActiPatch study on a different musculoskeletal location to get general musculoskeletal clearance, thus serving as a replacement for the back-pain study. The neck study directly compares the effectiveness of ActiPatch to that of prescription NSAID pills. Subjects were randomly assigned either to receive the standard of care treatment (cox-2 inhibitor) or ActiPatch. Interim results demonstrate that the ActiPatch is statistically significantly superior to the prescription NAID drug in reducing neck pain.

CE Mark Status Update

The ISO certification process at our manufacturer’s facility is going on briskly, while the technical review process with the notified body is nearing completion. The ISO certification, along with the technical file review comprise the two parts required to meet current CE mark requirements.

Mr. Bill Monn, who retired as VP of Logistics/Production at BioElectronics in 2018, is working with us as a consultant to assist in timely completion of the CE mark project.

Sales and Marketing Development

Walmart. The Walmart meeting went really well. At this point we have been asked by the buyer to show a couple things of interest. The item is very well received, and they have a desire to find product to fill a need in pain management for patients looking for alternatives to therapies that are not working. Mostly NSAIDs and opioids. The buyer has asked us to demonstrate our ability to drive sales through Walmart.com and then have another discussion at the end of September or August. We were one of thousands of companies to meet with this buyer for a 30-minute appointment. This appointment is no different than any other appointment where you as a vendor are asked to attend. There is interest here given our ability to prove in the market a product.
ActiPatch has been available through Performance Health on DSSI for the last few months for HCR ManorCare facilities. A presentation about ActiPatch was presented at their corporate meeting with upper business managers/operators. There was a lot of positive interest and they felt that they would soon facilitate adoption of ActiPatch into their centers. HCR ManorCare was happy to report that the product training went extremely well, and they have many therapists and patients “singing the praises” of the products. They have been ordering consistently in most of their centers and are happy to see their therapists offering ActiPatch as a treatment option for pain relief.
Endonovo Therapeutics, Inc. makers of a pulsed electromagnetic device has filed a lawsuit alleging we have violated their patents which were issued 2 years after our new patents. The lawsuit was filed in the Federal District Court in Los Angeles, California. We have retained an experienced patent litigator to file our response and to dispose of the case.
Disclosure: This newsletter is part of the bimonthly investor update; BioElectronics Corporation will be sending out this publication on the 1st and 16th (or the closest Monday) of every month. If you have further questions, please email investors@bielcorp.com.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 35

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 83

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 80

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 5

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 55

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 92

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading

Top 5 Most Recently Viewed Articles

BGSF Stock Declines as Company Reassesses Market Strategies

Updated Category News Views 181

BGSF Faces Market Headwinds as Stock Hits 52-Week Low In the midst of a tough market landscape, BG Staffing Inc (NYSE: BGSF) has seen its stock hit a 52-week low, dropping to $5.13. This decline mirrors a significant reduction in share value, with a notable 44.7% decrease over the past year. The current economic climate has prompted a cautious approach among investors,...

Continue Reading
Datadog's Earnings Predictions and Market Outlook for 2025

Updated Category News Views 254

What to Expect from Datadog's Earnings Announcement Datadog (NASDAQ: DDOG) is gearing up to announce its latest quarterly earnings, generating considerable interest among investors. Understanding the key metrics and expectations surrounding this event can be crucial for those looking to navigate the market effectively. Analysts' Expectations for Earnings Analysts...

Continue Reading
Investors Can Join Metagenomi, Inc. Securities Class Action

Updated Category News Views 245

Understanding Opportunities for Metagenomi, Inc. Investors Investing in stocks, especially during an initial public offering (IPO), carries risks, but it also presents unique opportunities. If you have purchased shares of Metagenomi, Inc. (NASDAQ: MGX), you might be eligible for compensation as part of a class action lawsuit. This opportunity has been highlighted by...

Continue Reading
Recent Market Trends and Insights on MongoDB Options Movements

Updated Category News Views 139

A Deep Dive into MongoDB's Options Activity Recently, attention has shifted towards MongoDB (NASDAQ: MDB), as financial giants display significant bearish moves that have piqued the interest of traders and analysts alike. An examination of MongoDB's options activity has unveiled a notable pattern, indicating varied sentiments in the market. In the latest analysis, we...

Continue Reading
Sotherly Hotels Inc. Revises Dividend Tax Treatment Details

Updated Category News Views 112

Understanding Recent Changes in Dividend Tax Treatment Sotherly Hotels Inc. (NASDAQ: SOHO), a notable player in the lodging industry, has recently announced amendments regarding the estimated income tax classification for its 2024 distributions related to the Series D preferred shares. This revision, first mentioned on February 18, arises from inaccuracies found in the...

Continue Reading